CURRICULUM VITAE

Adrienne Michelle Vasquez, LVN/ Research Nurse II

Research Affiliation

Anaheim Clinical Trials
2441 W. La Palma Ave Suite 140
Anaheim, CA 92801

Professional Licensure

State of Issue: California
License Type: Licensed Vocational Nurse
License #: 277619

Professional Experience

2024 – Present	Anaheim Clinical Trials 2441 W. La Palma Ave Suite 140 Anaheim, CA Clinical Researcher Coordinator
2021 – Present	Anaheim Clinical Trials 2441 W. La Palma Ave Suite 140 Anaheim, CA Research Nurse II
2021 – 2023	Anaheim Clinical Trials 2441 W. La Palma Ave Suite 140 Anaheim, CA Surgical PACU Nurse
2020 – 2021	Anaheim Clinical Trials 2441 W. La Palma Ave Suite 140 Anaheim, CA Research Nurse
2014 – 2020	Anaheim Clinical Trials 1085 N. Harbor Blvd Anaheim, CA Research Nurse

---

Education

2011 – 2013	American Career College Anaheim, CA Licensed Vocational Nurse
2008 – 2011	Memorial Care Long Beach, CA Wound Care / Med-Surg / Pre & Post Op

2006 – 2011 Pioneer Medical
Downey, CA
Internal Medicine / After Care

Research Experience (2024 - Present)

PHASE I

Healthy Adults

2024 **ECCOGENE**: A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of XXXX on the Single Dose Pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

2024 **ELI LILLY AND COMPANY**: A Bioequivalence Study of Subcutaneous Injections of Citrate-Free XXXX solution Using a 1mL Autoinjector and an Investigational 2mL Autoinjector in Healthy Participants

Dermatology

2024 **ELI LILLY AND COMPANY**: a Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of XXXX in Healthy Participants, a Multiple-Ascending Dose Study of XXXX in Patients with Atopic Dermatitis, and an Open-Label Multiple-Dose Evaluation of the Safety and Tolerability of Prednisone in Health Participants.

Endocrinology/Metabolic

2024 **ABBVIE**: An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX-XXX in Healthy Adult Japanese and Han Chinese Subjects

2024 **AMGEN:** A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of AMG 133 Administered Subcutaneously in Subjects with Overweight or Obesity

2024 **ELI LILLY AND COMPANY**: A Single- and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants with Type 2 Diabetes Mellitus

2024 **ELI LILLY AND COMPANY**: Single-and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of XXXX Following Oral Dosing in Healthy Participants

2024 **PFIZER**: A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to assess the Safety, Tolerability, and Pharmacokinetics of

Multiple Escalating Oral Doses of XXXX in Adult Participants with Type 2 Diabetes Mellitus

Ethnic Bridging

2024 **BRISTOLMYERSQUIBB:** A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Safety, Tolerability, Pharmacodynamics of Orally Administered XXXX in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

2024 **ELI LILLY AND COMPANY**: Single-and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of XXXX Following Oral Dosing in Healthy Participants

Gastroenterology

2024 **ECCOGENE**: An Open-Label, Randomized, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Current Tablet Formulation (F1) Compared to New Table Formulation (F2) of XXXX and Food Effects on F1 and F2 XXXX in Healthy Participants

Immunology

2024 **GILEAD**: A Phase 1a Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Different Formulations of Subcutaneous and/or Intramuscular XXXX in Healthy Participants

Neurology

2024 **ADEL, INC. AND OSCOTEC INC.**: First in Human, Phase Ia/Ib Study for Safety, Tolerability, Pharmacokinetics, and Clinical Activity Evaluation of XXXX in Healthy Participants and in Participants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer

Vaccine

2024 **PUBLIC HEALTH VACCINES**: A Phase 1b Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prime-Boost Regimen of Three Dose Levels of XXXX, a Nipah Virus Vaccine Candidate (rVSV-ΔG-EBOV GP-NiVG) in Healthy Adults

2024 **PFIZER**: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXX Vaccines Against Influenza in Healthy Adults

Other Indication

2024 **PFIZER**: A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two XXXX Film-

Coated Tablet Formulations Administered as 150 MG Under Fasted Conditions

PHASE II – IV

Pain (Acute – Post Operative)

2024 **CALI BIOSCIENCES**: A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of XXXX in the Management of Postoperative Pain after Open Inguinal Herniorrhaphy.

2024 **VIATRIS:** A Multi-Center, Randomized, Double-Blind, Placebo- (Double Dummy) and Active-Controlled, Parallel-Group Study of XXXX for the Treatment of Acute Postoperative Pain Following Bunionectomy

2024 **VIATRIS:** A Multi-Center, Randomized, Double-Blind, Placebo- (Double Dummy) and Active-Controlled, Parallel-Group Study of XXXX for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

Vaccine

2024 **ICOSAVAX**: a Phase 3, global, randomized, modified double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity, and safety of XXX-XXX, a Respiratory Syncytial Virus (RSV) and Human Metaneumovirus (hMPV) Virus-Like Particle (VLP) vaccine, in adults 60 years of age and older.

2024 **ICOSAVAX**: A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize the Safety and Immunogenicity of XXXX in Adults 60 Years of Age and older.

PHASE I

Healthy Adults

2023 **ABBVIE**: A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Vials Manufactured by Two Different Processes

2023 **ONENESS:** A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study to Evaluate the Safety and Bridging Pharmacokinetics Profile of XXXX for Single Subcutaneous Administration in Healthy Adults

2023 **PFIZER:** A Phase 1, Open-Label, Randomized Study with a 5-Period, 4-Sequence, Crossover Design to Compare the Single Dose Pharmacokinetics Between Immediate and Modified Release Formulations of XXXX Administered Orally to Healthy Adult Participants

2023 **VIATRIS:** A Randomized, Double-Blind, 3-arm Parallel Phase 1 Study to Assess Pharmacokinetics, Safety and Tolerability of XXXX Following a

Single Dose of 420 mg Intravenous Infusion Compared to the EU and US Marketed Drug Product (Perjeta®) in Healthy Male Volunteers

Cardiovascular

2023 **BRISTOL-MYERS SQUIBB**: A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Precious MyoKardia Formulation of XXXX and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants

2023 **BRISTOL-MYERS SQUIBB:** An Open-label, Randomized, Single-dose, Three-way Crossover Study to Establish Bioequivalence of 5 mg XXXX Capsule 1 and 5 × 1 mg XXXX Capsule 2 to 5 mg XXXX Capsule 2 in Healthy Participants

2023 **PFIZER:** A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of XXXX in Healthy Adult Participants and Repeat Doses in Participants with Pulmonary Arterial Hypertension

Dermatology

2023 **ABBIVE:** A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of XXXX in Vials Manufactured by Two Different Processes.

Endocrinology/Metabolic

2023 **GASHERBRUM:** A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXXX in Adult Overweight or Obese Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus on Metformin

Ethnic Bridging

2023 **ABBVIE**: A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects

2023 **ABBVIE:** An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects

2023 **BRISTOL-MYERS SQUIBB:** A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Caucasian Participants

2023 **ELI LILLY & CO:** A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, and Pharmacokinetics with Single Intravenous Ascending Doses and Single and Multiple Subcutaneous Doses of XXXX in Healthy Participants, Including First-Generation Japanese Participants

2023 **GASHERBRUM:** A Phase 1, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXXX in Japanese and Non-Japanese Healthy Volunteers

2023 **GILEAD:** A Phase 1 Single-Dose Study to Evaluate the Pharmacokinetics and Tolerability of XXXX (XXXX) in Healthy Japanese and White Participants

2023 **IDORSIA:** A Single-Center, Open-Label, Randomized, Crossover Phase 1 Trial to Investigate Bioequivalence Between 5 x 10 mg tablets and 2 x 25 mg tablets of XXXX in Healthy Male and Female Japanese Participants

2023 **VENTYX:** A Phase 1, Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXX Following an Oral Administration in Healthy Japanese and Caucasian Subjects

Hepatology

2023 **PFIZER:** A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess Pharmacokinetics, Safety and Tolerability of XXXX in Adult Participants with Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment

Gastroenterology

2023 **PFIZER:** A Phase 1B Open-Label/Phase 2 Double-Blind Placebo-Controlled Study for Pharmacodynamic Activity, Pharmacokinetics, Safety and Tolerability of XXXX in Patients with Celiac Disease

Immunology

2023 **BIOGEN:** A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adult Participants

2023 **BRISTOL-MYERS SQUIBB:** A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Ascending Doses of XXXX in Healthy Adult Participants (Immunomodulator)

2023 **BIOGEN:** A Phase 1, randomized, Double-Blind, Crossover Study to Evaluate the Bioequivalence of XXXX (XXXX, XXXX) Manufactured at Biogen Oral Solid Dose (OSD) in Healthy Adult Participants

Neurology

2023 **BRISTOL-MYERS SQUIBB:** A Phase 1, Open-label, Randomized, Parallel-group, Single dose Study to Assess the Relative Bioavailability of a New XXXX Immediate-release Tablet Formulation Compared to a Reference Enteric Capsule (Delayed-release) Formulation, and to Assess the Effect of Food on the Pharmacokinetics of Immediate-release Tablet Formulation in Healthy Adult Participants

Psychiatry

2023 **ABBVIE:** Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of XXXX in Healthy Adult Subjects

Vaccine

2023 **PFIZER**: A Phase 1 Randomized and Phase 2 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Immunopersistence of a XXXX Vaccine Administered in a 2-Dose Regimen with Novel Adjuvants in Healthy Adults

Women's Health

2023 **PFIZER:** A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Two Steady-State Dose Levels of XXXX on the Pharmacokinetics of Single-Dose XXXX, XXXX and an Oral Contraceptive, and the Effect of Steady-State XXXX on the Pharmacokinetics of Single-Dose XXXX, in Obese Adult Female Participants

Other Indication

2023 **GILEAD:** A Phase 1 Study to Evaluate Transporter and Cytochrome P450 Enzyme (CYP)-Mediated Drug-Drug Interactions Between XXXX and XXXX, XXXX, and XXXX in Healthy Participants

2023 **VISTERRA:** A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose, First-in-Human, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Male and Female Participants

PHASE II-IV

Dermatology

2023 **AMGEN:** A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind, Study to Assess the Efficacy, Safety and Tolerability of XXXX (XXXX) Monotherapy in Adult Subjects with Moderate-to-severe Atopic Dermatitis (AD).

Endocrinology/Metabolic

2023 **JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO.**: A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of XXX-XXX in Participants with Gout

Pain (Acute – Post Operative)

2023 **VERTEX:** A Phase 3, randomize, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After a Bunionectomy

2023 **VERTEX:** A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After an Abdominoplasty

PHASE I

Healthy Adults

2022 **ABBVIE:** A Phase 1 Study in Healthy Subjects to Evaluate the Bioavailability of XXXX 150 mg/mL Formulation in the 180 mg Prefilled Syringe Relative to 90 mg/mL Formulation in the 90 mg Prefilled Syringe

2022 **ABBVIE:** Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of XXXX, XXXX and XXXX, and Potential of XXXX for CYP3A Induction in Healthy Volunteers

2022 **BRAINTREE**: Examination of Gastric Mucosal Abnormalities Before and After Bowel Preparation

2022 **BRISTOL-MYERS QUIBB:** An Open-Label, Single-Sequence, Crossover Study to Investigate the Interaction of Multiple Doses of XXXX at Steady State and Multiple Doses of a Combined Oral Hormonal Contraceptive (XXXX XXXX/XXXX) in Healthy Female Participants

2022 **BRISTOL-MYERS SQUIBB**: A Phase I, Open-Label, Randomized, Two-part Parallel Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of XXXX (also known as XXXX and XXXX) Administered using Autoinjector versus using Prefilled Syringe, and to Evaluate the Pharmacokinetics of XXXX When Administered by Autoinjector at Different Injection Sites, in Healthy Participants.

2022 **EISAI**: An Open-Label, Parallel-Group, Randomized Study to Demonstrate the Bioequivalence of the Subcutaneous Formulation of XXXX Supplied in Vials and a Single Use Auto-Injector

2022 **PFIZER:** A Phase 1, Open-Label, Randomized, Single Dose, 2-Way Crossover Study Assessing Pharmacokinetic Comparability of Two XXXX Presentations, On-Body Injector and Prefilled Syringe, In Healthy Participants

Endocrinology/Metabolic

2022 **ECCOGENE:** A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and in Patients with Type 2 Diabetes Mellitus

2022 **ELI LILLY & CO:** A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX Alone and in Combination with XXXX in Patients with Type 2 Diabetes

Ethnic Bridging

2022 **ABBVIE:** This is a Phase 1, double-blind, sequential, placebo-controlled, single center, randomized study in which healthy Japanese subjects will receive a single XXXX dose or placebo. Healthy Han Chinese subjects will also receive a single XXXX dose, but no Han Chinese subjects will receive placebo, and there will be no randomization of Han Chinese subjects. A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult, Japanese, and Han Chinese Subjects

2022 **BIOGEN:** An Open-Label, Parallel-Group, Phase 1 Study to Evaluate The Pharmacokinetics, Safety, And Tolerability Of XXXX In Healthy Adult Japanese, Chinese, And Caucasian Participants

2022 **BIOGEN**: A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of XXXX (XXXX) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers

2022 **BRISTOL-MYERS SQUIBB:** A Double-blind, Placebo-controlled, Randomized, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants of Japanese Descent

2022 **BRISTOL-MYERS SQUIBB:** A Phase 1 Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of XXXX in Healthy Adult Japanese Participants

2022 **BRISTOL-MYERS SQUIBB:** A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants including Healthy Participants of Japanese Ethnicity and an Open-label Assessment of Food Effects on the Relative Bioavailability of XXXX / XXXX

2022 **CINCOR:** A Phase 1 Single and Multiple Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Japanese and Caucasian Subjects

2022 **GILEAD SCIENCES:** A Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese Participants

2022 **INTRA-CELLULAR:** An Open-Label, Ascending Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Japanese and Healthy Caucasian Subjects

2022 **SUMITOVANT**: A Phase I Randomized, Double-Blind, Multi-Part, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Dose of XXXX Alone and Co-administered with Meropenem in Healthy Subjects

Other Indication

2022 **CSL BEHRING**: A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacokinetic Properties of XXXX Administered by Subcutaneous Autoinjector to Prefilled Syringe in Healthy Adult Subjects

PHASE II-IV

Endocrinology/Metabolic

2022 **PFIZER: A** Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of XXXX, and Open-Label Oral XXXX, in Adults with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin, and Separately XXXX Compared to Matching Placebo in Adults with Obesity but Without T2DM.

Pain (Acute – Post Operative)

2022 **TEIKOKU PHARMA USA, INC.**: A Double-Blind, Placebo-Controlled, Evaluation of the XXXX Transdermal Systems for Postoperative Analgesia Following Abdominoplasty

Vaccine

2022 **PFIZER:** A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older

2022 **PFIZER**: An Interventional, Randomized, Active-Controlled, Phase 2 Observer-Blind Study to Investigate the Safety, Tolerability, and Immunogenicity of a Bivalent XXXX RNA-Based Vaccine Candidate as a Booster Dose in Covid-19 Vaccine-Experienced Healthy Adults.

Research Experience (Pre-2022)

ABBVIE
Research Nurse. A Phase 1 Open-Label Study to Assess the Pharmacokinetics, Safety, and Tolerability of the C0-Administration of XXXXXXX (XXXXXXXXX, XXXXXXXXXXXX, and XXXXXXXXX XXXXXXXXXX XXXXXXXX) Tablets with XXX-XXX and XXX-XXX in HIV-Mono-Infected Adult Subjects.

Research Nurse. A Pharmacokinetic Study to Evaluate the Effects of Showering and Skin Washing after Administration of XXX-XXXXXX in Hypogonadal Males.

Research Nurse. A Randomized, double-Blind, Placebo-Controlled, multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX-XXX in Healthy Volunteers and in Subjects with Chronic Plaque Psoriasis.

Research Nurse. A Multicenter, Randomized, Double-blind, Placebo-Controlled study to Assess the Safety and Efficacy of Ranibizumab Using a New Formula for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis.

Research Nurse. A Phase 1, Pharmacokinetic Comparability Study of Intravenous and Subcutaneous Administration of XXXX in Healthy Subjects

ACADIA

Research Nurse II. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy).

ALLERGAN

Research Nurse. AN Open-Label, Multiple- Dose, Two-Period, Two-Way Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXXXXXXXXX in Healthy Japanese and Caucasian Subjects

Research Nurse. A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXXXXXXX in Healthy Japanese and Caucasian Participants

AMGEN

Research Nurse II. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG XXXX in Subjects with Obesity.

Research Nurse II. An Open-Label, Randomized, Single-Dose, Parallel-Group Study in Healthy Subjects to Assess the Comparability of a Single Subcutaneous Dose of XXXX When Delivered Manually from A Prefilled Syringe Versus Delivered by an Autoinjector.

Research Nurse. A Randomized, Single-Blind, Single-Dose, 2-Arm, Parallel Group Study to Determine the Pharmacokinetic Equivalence of XXX XXX and XXXXXXXXXXX (XXXXXXXXX) In Healthy Japanese Male Subjects.

Research Nurse. A Randomized, Single-Blind, Single-Dose, 2-Arm, Parallel Group Study to Determine the Pharmacokinetic Bioequivalence of XXX XXX and XXXXXXXXXX (XXXXXX) In Healthy Adult Japanese Subjects.

Research Nurse. A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of XXX XXX in Healthy Japanese Subject.

Research Nurse. An Open Label Randomized, Parallel Group Study in Healthy Volunteers to Assess the Relative Bioavailability Of 3 Different XXX XXX Treatments

Research Nurse. An Exploratory Phase 0 Study in Healthy Volunteers to Acquire Data Form an Active Tracker and Vital Sign Medical Device Patch

Research Nurse. A Phase 1, Randomized, Double- Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXX XXX in Healthy Subjects

Research Nurse. An Open Label Randomized, Parallel Group Study in Healthy Volunteers to Assess the Relative Bioavailability Of 2 Different XXX XXX Treatments

Research Nurse. A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of XXX XXX and A Combined Oral Contraceptive in Healthy Female Subjects

Research Nurse. An Open Label Randomized Parallel Group Study in Healthy Volunteers To Assess The Relative Bioavailability Of 2 Different XXXXX XXXXXX
Prefilled Syringe Treatments

Research Nurse. An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability Of XXX-XXX in Japanese Subjects with Elevated Plasma Lipoprotein(A)

Research Nurse. A Phase 1, Randomized, Double-Blind, Placebo- Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG XXX in Subjects with Obesity

Research Nurse. A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Obesity.

ANAPTYSBIO
Research Nurse. A Phase 1, single-dose trial to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of XXXXXX in healthy Japanese and Caucasian subjects received IRB approval.

APPLIED THERAPEUTICS
Research Nurse. A Phase 1-2, Dose-Escalating, 4-Part Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of XX-XXX in Healthy Adult Subjects and Adult Subjects with Classic Galactosemia (CG)

ARDEA
Research Nurse. A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of XXXXXXXX Administered in Combination with XXXXXXXXXX Compared to XXXXXXXXXX Administered Alone in Adult Subjects with Gout.

Research Nurse. A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of XXXXXXXX Administered in Combination with XXXXXXXXXX Compared to XXXXXXXXXX Administered Alone in Adult Subjects with Gout.

ARIES
Research Nurse. An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Caucasian Participants

ASTRAZENECA
Research Nurse. A Phase I, Open-label, Randomized, Single-dose Study of XXXX in Healthy Subjects to Evaluate the Effect of Proton-pump Inhibitor (XXXX) on XXXX Capsule when Administered Orally with COCA-COLA.

BIOGEN

Research Nurse II. A Phase 1, Randomized, Blinded, Placebo-Controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adults.

Research Nurse II. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Non-Japanese Participants.

Research Nurse. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX XXXX (XXXX) in Healthy Male Japanese and Caucasian Study Participants.

Research Nurse. A Phase 1, Randomized, Blinded, Placebo- Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXXXX in Healthy Adult Participants

Research Nurse. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXXXXX in Healthy Japanese and Non-Japanese Participants

Research Nurse. An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXXXXX in Healthy Adult Japanese, Chinese, and Caucasian Participants

Research Nurse. A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of XXXXXXXXXXX (XXXXXXX) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers

BMS

Research Nurse II. An Open-label, Randomized, Two-Period Cross-over Study to Investigate the Relative Bioavailability of XXXX in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration with Auto-injector Versus Pre-filled Syringe.

Research Nurse. A Phase 1, Open-Label, Drug-Drug Interaction Study between XXXXXXXXX and XXX/XXX/XXX-XXXXXX and between XXXXXXXXXXXXX/XXXXXXXX and XXX/XXX/XXXXXXXXX XXX + XXXX mg XXX XXXXXX.

Research Nurse. A Randomized, Placebo-Controlled, Single-And Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunologic Effects Of XXX-XXXXXXX and A Relative Bioavailability Study in Healthy Participants

Research Nurse. A Randomized, Double-Blind, Placebo- Controlled Single and Multiple, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Of XXX-XXXXXX in Healthy Participants

Research Nurse. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXXXXXXXXXXXXXXX in Healthy Participants including Healthy Participants of Japanese Ethnicity and an Open-label Assessment of Food Effects on the Relative Bioavailability of XXXXXXXXXXXXXXXX

Research Nurse. A Phase I, Open-Label, Randomized, Two-part Parallel Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of XXXXXXXXX (also known as XX-XXXXXX and XXX-XXXXXX) Administered using Autoinjector versus using Prefilled Syringe, and to Evaluate the Pharmacokinetics of XXXXXXXXXX When Administered by Autoinjector at Different Injection Sites, in Healthy Participants

CALI PHARMACEUTICALS

Research Nurse II. A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of XXXX in the Management of Postoperative Pain After Open Inguinal Herniorrhaphy.

CELGENE

Research Nurse II. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Active-Controlled (XXXX), Comparator-Controlled (XXXX), Multiple-Dose, Parallel-Group Study to Investigate the Pressor Effect of Oral XXXX During XXXX Treatment in Healthy Adult Subjects.

Research Nurse. A Phase 1. Randomized, Open-Label, Single-Dose to Evaluate the Pharmacokinetics of XX-XXXXX in Healthy Japanese and Caucasian Adult Subjects

Research Nurse. A Phase1, Randomized, Double-Blind, Placebo-Controlled, Active-Controlled (XXXXXXX), Comparator-Controlled (XXXXXXX), Multiple-Dose, Parallel-Group study to Investigate the pressor effect of oral Tyramine during Ozanimod treatment in healthy adult subjects

CELLTRION

Research Nurse. A Randomized, Double-blind, Two-arm, Parallel-group, Single-dose Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of Two Formulations of XXXXXXXXXX (XX-XX and US-licensed XXXXXXXXX) in Healthy Subjects.

Research Nurse. A Phase 1, Randomized, Double-blind, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of XXXX and EU-Approved XXXX in Healthy Japanese Male Subjects

COMPLEXA

Research Nurse. An Open Label, Non-Randomized Study of Safety, Tolerability and Pharmacokinetics of Intravenous XXX-XX Emulsion in Subjects with Stage 3 and 4 Chronic Kidney Injury.

CSL BEHRING

Research Nurse. A 2-Part, Phase 1, Single Center, Open-label, Single Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous and Intravenous XXXX in Healthy Adult Japanese and Caucasian Subjects.

Research Nurse. A Phase 1, Randomized, Open-label, Parallel-group Study to Compare the Pharmacokinetic Properties of XXXXXX Administered by Subcutaneous Prefilled Syringe Assembled to Autoinjector to Prefilled Syringe Assembled to Needle Safety Device in Healthy Adult Subjects

DMID-NIH

Research Nurse. A Two- Part Phase 1 Study to Establish and Compare the Safety and Local Tolerability of Two Nasal Formulations of XX-XX for XXXXXXXXXXXXXX of

XXXXXXXXXXXX XXXXXX. A Previously Investigated XXXX/XX XXXXXXXXXXX XXX Formulation Versus a Modified Formulation.

DR. REDDY's LABORATORIES
Research Nurse. An Open Label, Balanced, Randomized, Multi-Center, 2-Trewatment, 4-Period, 2-Sequence, Single-dose, Crossover Study to Assess the Bioequivalence and Safety of XXXXXXXXXXX XXX XXXX% OF Dr. Reddy's Laboratories, Inc., USA Compared with XXXXXXXX XXXX% Abbott Laboratories, North Chicago, USA in Healthy Human Male Hypogonadal Patients.

EISAI
Research Nurse II. An Open-Label , Parallel-Group, Randomized Study to Evaluate the Absolute Bioavailability of a Single Dose Subcutaneous Administration of XXXX in Healthy Subjects.

ELI LILLY
Research Nurse II. An Open-Label, Randomized Study To Evaluate The Bioequivalence Of XXXX Tablet And Capsule Formulations

Research Nurse II. A Phase 2 Study of Once-Weekly XXXX Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities.

Research Nurse II. A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants.

Research Nurse II. A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Non-Japanese and Japanese Participants.

Research Nurse. Evaluation of the effect of Mirikizumab on the pharmacokinetics of cytochrome XXXX substrates in patients with moderate to severe plaque psoriasis

Research Nurse. A Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of XXXX in Patients with Type 2 Diabetes Mellitus.

ESPERION
Research Nurse. A Phase 1, Placebo-Controlled, Randomized, Double Blind, Parallel Group Study to Evaluate Safety, Tolerability, and XXXX Pharmacokinetics in Patients with Type 2 Diabetes Receiving XXXX and XXXX for 2 Weeks.

Research Nurse. A randomized, Double-Blind, Placebo-Controlled Single-Ascending and Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Bempedoic Acid in healthy Japanese and Additional East Asian Ethnicity Cohorts

ESTEVE
Research Nurse. A Randomized, Double blind, Active- (XXXXXXXX and XXXXXXXXX) and placebo- controlled, Parallel Groups, Phase 3 Clinical Trial to Establish the Efficacy of Co-crystal XXXXXX for the Management of Moderate to Severe Post-surgical Pain after Bunionectomy.

GENERON
Research Nurse. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Male Subjects.

GENENTECH
Research Nurse. A Phase 1, Open Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of XXXX in Subjects with Mild, Moderate, or Severe Hepatic Impairment compared to Healthy Subjects

GILEAD
Research Nurse II. A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between XXXX (XXX) and XXXX (XXX).

Research Nurse II. A Phase 1 Drug Interaction Study Evaluating the Effect of XXXX on the Pharmacokinetics of the Combined Hormonal Oral Contraceptive XXXX/XXXX in Healthy Female Subjects.

Research Nurse. A Randomized, Double blind, Placebo- Controlled Phase 1 Study to Evaluate the Testicular Safety of XX-XXXX in Healthy Adult Males

GLAXOSMITHKLINE
Research Nurse II. A Two-Part, Randomized, Double-Blind, Single-Dose, Crossover Study To Compare Formulations Produced By Two Methods Of Manufacture For Bioequivalence And Dissolution In Healthy Adult Volunteers

Research Nurse II. A Phase I, Single-Blind, Randomized, Single-Dose Clinical Pharmacology Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of XXXX Vs Placebo By Intravenous Or Intramuscular Administration In Healthy Japanese And Caucasian Participants.

Research Nurse. A Phase II Multicenter, Parallel Group, Randomized, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following 12 Weeks of Oral Administration of XXXXXXXXXX with XXXXXX, XXXXXX and XXXXXXXXX in Treatment-Naïve Subjects with Chronic Genotype 1 or 4 Hepatitis C Infection

Research Nurse. A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX Administered Subcutaneously in Healthy Participants.

GOSSAMER
Research Nurse. A Phase 1a, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of tablet formulations of XXXXX in healthy male and female volunteers.

GW PHARMA
Research Nurse. An Open Label, Randomized, Single-Dosed, Two-Sequences, Two-Treatment, Four-Period, Crossover Study to Evaluate the Effects of XXXX on the Pharmacokinetics (PK) of XXXX in Healthy Subjects with Cannabis Experience.

HERON
Research Nurse. A Phase 2, Randomized, Double Blind, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of XXX XXX Administered Via Injection or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Research Nurse. A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered XXX-XXX-XXX for Postoperative Analgesia Following Bunionectomy

Research Nurse. A Phase 3, Randomized, Double Blind, Saline Placebo- and Active- Controlled, Multicenter study of XXX-XXX via local Administration for Postoperative Analgesia and Decreased Opioid use following Unilateral Open Inguinal Herniorrhaphy

Research Nurse. A Phase 3, Randomized, Double Blind, Saline Placebo- and Active- Controlled, Multicenter study of XXX-XXX via local Administration for Postoperative Analgesia and Decreased Opioid use following Unilateral Simple Bunionectomy

Research Nurse. A Randomized, Phase 4 Study of the Efficacy, Safety, and Pharmacokinetics of XXXXXXXXXXX Administered as XXXXXXXXX XXXXXXXXXX or Continuous Infusion Via Elastomeric Pump Following Unilateral Open Inguinal Herniorrhaphy

I1F-MC-RHBU(a)

Research Nurse. Evaluation of the Effect of XXXXXXXXXX on the Pharmacokinetics of Cytochrome XXXX Substrates in Patients with Moderate- to Severe Plaque Psoriasis

IDORSIA

Research Nurse. A Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Tolerability, Safety, And Pharmacokinetics After Multiple-Dose Administration of XX XX XXXXXXXXXXX in Healthy Japanese and Caucasian Subjects.

Research Nurse. A single-center, double-blind, placebo-controlled, randomized study to investigate the tolerability, safety, and pharmacokinetics after multiple-dose administration of XX XX XXXXXXXXXXX in healthy Japanese and Caucasian subjects.

INSYS

Research Nurse. A Phase 3, Randomized, Double Blind, Multiple Dose, Parallel Group, Placebo Controlled Study of XXXXXXXXXXXX Sublingual Spray (XXXXXXX, XXXXXXX, And XXXXXXXXX) For the Treatment of Moderate to Severe Pain

JANSSEN VACCINES & PREVENTION

Research Nurse. A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an XXXX-XXX-XXXX Based Regimen in The Prevention Of XX-XXX Confirmed XXX Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

KENYOS BIO

Research Nurse. Kanyos Bio XXXX, A Phase 1 Study of The Safety and Tolerability of Single and Multiple Doses of XXXX in Patients with Celiac Disease.

MEDICAGO

Research Nurse. A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of an XXX-XXXXX XXXXX VLP Influenza Vaccine in Adults 18-64 Years of Age

MEDIMMUNE

Research Nurse. A Phase 1, Randomized, Blinded, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of XXXXXXXX in Overweight/Obese Subjects of Japanese or Chinese Descent

MILLENDO

Research Nurse. A Phase 1 Single Ascending Dose Study in Healthy Men, A Food-Effect Study in Postmenopausal Women, and A Multiple Ascending Dose Study in Postmenopausal Women with Vasomotor Symptoms (VMS) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX.

NOVARTIS

Research Nurse. A Randomized, Placebo-Controlled First-In -Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled XXXX in Healthy Subjects.

Research Nurse. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Modulation of Immune Response to T-Cell, Dependent and T-Cell independent Antigen Stimuli by Preceding, Concomitant and Interrupted Administration of Multiple Therapeutic Doses.

Research Nurse. A Two Part Randomized Double Blind, Parallel Group, and Placebo-Controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of XXX XXX in Patients with Moderately Impaired Renal Function on Angiotensin Receptor Blockers.

Research Nurse. First in Human Single and Multiple Dose Escalation Study of XXXXXX for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Adult Volunteers

PFIZER

Research Nurse II. A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of Two Steady-State Dose Levels of XXXX On the Pharmacokinetics of Single Oral Doses of XXXX and XXXX In Healthy Adults and An Oral Contraceptive in Healthy Post-Menopausal Female

Research Nurse. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of XXXX Given as Monotherapy to Adults with Type 2 Diabetes Mellitus.

Research Nurse. A Phase 1, Randomized, Double-Blind, Third Party, Placebo-Controlled, Single and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XX-XXXXXXXX in Healthy Subjects and Subjects with Plaque Psoriasis and Bioavailability of a Tablet Formulation Relative to Suspension Formulation and the Effect of Food on Tablet Formulation of XX-XXXXXXXX.

Research Nurse. A Phase 1, Non-Randomized, Open-Label, Single dose study to evaluate the effect of Renal Impairment on the Pharmacokinetics, safety, and tolerability of XXXXXXXXXX (XX-XXXXXXXX) in subjects with Renal Impairment and in Healthy subjects

Research Nurse. A Phase 1, within cohort, Randomized, Double-Blind, Third Party, OPEN, Placebo-Controlled, Single and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XX-XXXXXXXX in Healthy Subjects and Subjects with Plaque Psoriasis

Research Nurse. A Phase 1, Randomized, Double-Blind, Sponsor- Open, Placebo- Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Escalating Oral Doses of XX-XXXXXXXX in Adult Subjects with Type 2 Diabetes Mellitus

Research Nurse. A Phase 1B, Randomized, Double-Blind (Sponsor-Open), Placebo- Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Multiple Oral Doses of XX-XXXXXXXX for 2 weeks in Adults with Nonalcoholic Fatty Liver Disease

Research Nurse. A Phase 1, Single Dose Open-Label Study to Evaluate the Pharmacokinetics of XXXXXXXXXX in Subjects with Impaired Renal Function

Research Nurse. A Phase 1, Single dose, Open-Label, Study to Evaluate the Pharmacokinetics of XXXXXXXXXX in Subjects with Impaired Renal Function

Research Nurse. A Phase 1, Randomized, Double Blind, Sponsor-open, Placebo-controlled study to evaluate the safety, Tolerability and Pharmacokinetics of single-dose, Subcutaneous Administration of XX-XXXXXXXXX to Healthy Adult Japanese Participants

Research Nurse. A Phase 2, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of XX-XXXXXXXXX in participants with moderate to severe plaque psoriasis

Research Nurse. A Phase 2b. Randomized, Double-blind, Vehicle-Controlled, Parallel-Group, Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of XX-XXXXXXXX Topical Cream Applied once or twice daily for 12 weeks in participants with mild to moderate chronic plaque psoriasis

Research Nurse. A Phase1, Randomized, Double-Blind, Sponsor-open, Placebo-Controlled study to assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of XX-XXXXXXXX in Adult Participants with type 2 Diabetes Mellitus

Research Nurse. A Phase 1, Open-Label, Fixed Sequence Study to Evaluate the Effect of Two Dose Levels of XXXX on the Pharmacokinetics of Single Oral Doses of Rosuvastatin and Midazolam, Administered Separately in Adult Participants with Obesity.

Research Nurse. A Phase 1 First in Human, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single- and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and Participants with Atopic Dermatitis.

POLPHARMA

Research Nurse. A Phase 1, Single Dose, Randomized, Double-Blind Parallel Group Study to Compare the Pharmacokinetics and Pharmacodynamics of XXXX with XXXX in Healthy Subjects.

PVP BIOLOGICS

Research Nurse. A Phase 1, Two-Part Study Assess the Safety, Tolerability, and Pharmacokinetics of XXXXXX and XXXXXX in Healthy Adult Volunteers and Adults with Celiac Disease and to Assess the Gluten Degradation Activity of XXXXXX and XXXXXX in Healthy Adult Volunteers

Research Nurse. A Phase 1, Two-Part Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXXXX and XXXXXX in Healthy Adult Volunteers and Adults with Celiac Disease and to Assess the Gluten Degradation Activity of XXXXXX and XXXXXX in Healthy Adult Volunteers

Research Nurse. A Phase 1, Four-Part Study to Assess the Safety, Tolerability, and Pharmacokinetics, and Gluten Degradation Activity pf XXXXXX, XXXXXX, and XXXXXX in health adult volunteers and to assess the safety, tolerability, and pharmacokinetics of XXXXXX and XXXXXX in adults with Celiac Disease

QED Therapeutics
Research Nurse II. A Phase 1, An Open-Label, Multiple Dose, Ethnic Sensitivity Study of XXXX (XXXX) XXXX mg in Japanese vs. Caucasian Healthy Subjects.

Research Nurse. An Open-label, Multiple-dose, Ethnic Sensitivity Study of XXXXXXXX (XXXXXX) 125mg in Health Japanese versus Matched Healthy Caucasian Subjects

RECRO
Research Nurse. A phase 3, Randomized, double-blind, Placebo-Controlled, Multicenter, Evaluation of Safety of XXXXX following Major Surgery

SHANTON
Research Nurse. A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-escalation study to evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of XXX-XXX in Gout Patients with Hyperuricemia

(STAMPOUT) INTERVEXION
Research Nurse. A Parallel-Group, Placebo-Controlled, Double-Blind Safety Study Of XXX-XXXX in Otherwise Healthy Subjects with XXXX (XXXX) Use Disorders. An Adequate Number of Subjects Will Be Enrolled to Ensure Approximately 42 Completers. Four Cohorts Will Receive Single Doses Of XXX-XXXX (XXXX or XXXX Mg/Kg) Or Placebo Followed by A Series of Weekly METH Challenges During A 23-Day Inpatient Stay

SYNERGY
Research Nurse. A Phase 0 Multi-Center study to explore the Postprandial Uroguanylin and Prouroguanylin Response in Healthy Adult Subjects

TAIWAN LIPOSOME COMPANY(TLC)
Research Nurse. A Phase 2, Randomized, Double-Blind, Comparator and Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of XXXXXX for Postsurgical Pain Management Following Bunionectomy

TAKEDA
Research Nurse. A Randomized, Double-Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of XXXXXXX XXXXXXXXXX XXXXXXX XXXXXXX XXXXXXXXX (XXX) in Healthy Adults.

Research Nurse. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Multiple Oral XXX-XXX Doses in Healthy Japanese Subjects and Subjects with Type 2 Diabetes Mellitus.

TEVA

Research Nurse II. An Open-Label, Randomized, Phase 1 Subcutaneous Single-Dose Study to Assess the Pharmacokinetics, Safety, Immunogenicity, and Tolerability of XXXX (Doses up to XXXX mg) in Healthy Adult Japanese and Caucasian Subjects.

THERAVANCE
Research Nurse. A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of XX-XXXX in Healthy Subjects and Subjects with Ulcerative Colitis (UC)

TREVENA
Research Nurse. A Phase 3, Multicenter, Randomized, Double Blind, Placebo- And Active-Controlled Study of XXXXXXXX (XXXXXX) For the Treatment of Moderate to Severe Acute Pain After Bunionectomy

UCB
Research Nurse II. A Placebo-Controlled, Double-Blind, Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics (PK) of XXXX XXXX in Healthy Japanese, Chinese, and Caucasian Participants

UPSHER-SMITH
Research Nurse. A Phase 4, Open-Label, Single-Arm Study to Evaluate the Effects of XXXX on 24-hour Ambulatory Blood Pressure Monitoring in Hypogonadal Men Using Therapeutic Testosterone Replacement Therapy.

VALEANT
Research Nurse. A phase 1b, Open-label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied XXX-XXX Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis

VECTURA
Research Nurse. A randomized, open-label, crossover trial to compare the pharmacokinetics, safety, and tolerability of single doses of XXXXX Inhalation Suspension delivered by the XXXXX Inhalation System (XXXXX) with single doses of budesonide delivered by a conventional jet nebulizer in healthy adult volunteers and adult asthma subjects.

VERTEX
Research Nurse II. A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After a Bunionectomy.

Research Nurse. A Phase 2 Randomized, Double blind, Placebo- controlled, 3- arm, Parallel- design Study of the efficacy and Safety of XX-XXX for Acute Pain following Bunionectomy.

VIVOZON
Research Nurse. A Multicenter, Randomized, Double-blind, parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX-XXX Injections for the Treatment of Postoperative Pain Following Bunionectomy

Research Nurse. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of XXX-XXX Injections for the Treatment of Post-Operative Pain following Abdominoplasty.

By signing this form, I confirm that the information provided is accurate and reflects my current qualifications.

_____ _____

Signature *Date of Signature*